Arrowhead reported early human target-engagement support for a brain-shuttling delivery approach using systemic RNAi dosing in healthy volunteers. The company framed the milestone as progress on central nervous system siRNA delivery, while also emphasizing an ongoing need to define the therapeutic window for tau knockdown. For the field, the update matters because CNS delivery remains a major limiter for RNA-modulating medicines, and tau biology continues to attract high-stakes investment despite prior mixed clinical outcomes.